BioMarin Collaborates with Allen Institute to Develop Gene Therapies for Rare Brain Diseases

 BioMarin Collaborates with Allen Institute to Develop Gene Therapies for Rare Brain Diseases

BioMarin Collaborates with Allen Institute to Develop Gene Therapies for Rare Brain Diseases

Shots:

  • BioMarin will receive an exclusive license to each program for research, development, and commercialization of the gene therapies
  • The collaboration will utilize Allen institute technologies to develop new gene therapies for rare genetic diseases of CNS by targeting gene expression to specific cells
  • Allen Institute has developed modified engineering AAVs to carry genes on specific types of neurons or other cells in the brain

Click here to­ read full press release/ article | Ref: BioMarin | Image: BioMarin

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post